| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 92 | 2024 | 262 | 17.100 |
Why?
|
| Interferon-beta | 42 | 2021 | 125 | 6.550 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 27 | 2024 | 54 | 6.540 |
Why?
|
| Immunosuppressive Agents | 14 | 2023 | 977 | 2.180 |
Why?
|
| Leukocytes, Mononuclear | 12 | 2023 | 196 | 2.110 |
Why?
|
| Immunologic Factors | 7 | 2021 | 170 | 1.820 |
Why?
|
| Adjuvants, Immunologic | 12 | 2021 | 167 | 1.420 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 2 | 2024 | 8 | 1.280 |
Why?
|
| Fingolimod Hydrochloride | 10 | 2021 | 29 | 1.220 |
Why?
|
| Interferon Type I | 5 | 2014 | 175 | 1.130 |
Why?
|
| T-Lymphocytes, Regulatory | 16 | 2021 | 295 | 1.080 |
Why?
|
| Insomnia, Fatal Familial | 2 | 2022 | 3 | 0.980 |
Why?
|
| Humans | 141 | 2024 | 86601 | 0.950 |
Why?
|
| Interferon beta-1a | 10 | 2023 | 18 | 0.950 |
Why?
|
| Neurodegenerative Diseases | 1 | 2024 | 44 | 0.930 |
Why?
|
| Dimethyl Fumarate | 2 | 2021 | 2 | 0.900 |
Why?
|
| Interferon beta-1b | 18 | 2018 | 39 | 0.820 |
Why?
|
| Meningitis | 1 | 2020 | 20 | 0.770 |
Why?
|
| Thymoma | 1 | 2020 | 30 | 0.760 |
Why?
|
| Neuromyelitis Optica | 4 | 2023 | 22 | 0.760 |
Why?
|
| Paresthesia | 1 | 2020 | 16 | 0.760 |
Why?
|
| Thymus Neoplasms | 1 | 2020 | 41 | 0.750 |
Why?
|
| Neuroprotection | 1 | 2019 | 7 | 0.720 |
Why?
|
| Evidence-Based Medicine | 2 | 2012 | 429 | 0.720 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2018 | 864 | 0.720 |
Why?
|
| Cholecalciferol | 1 | 2019 | 35 | 0.710 |
Why?
|
| T-Lymphocytes | 16 | 2022 | 1195 | 0.690 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 159 | 0.690 |
Why?
|
| Adult | 71 | 2023 | 25640 | 0.680 |
Why?
|
| Middle Aged | 54 | 2023 | 25017 | 0.680 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 365 | 0.640 |
Why?
|
| Receptors, Interferon | 3 | 2014 | 31 | 0.600 |
Why?
|
| Interleukin-10 | 5 | 2007 | 149 | 0.600 |
Why?
|
| GTP-Binding Proteins | 3 | 2012 | 146 | 0.600 |
Why?
|
| Magnetic Resonance Imaging | 20 | 2023 | 3352 | 0.600 |
Why?
|
| Injections, Subcutaneous | 2 | 2017 | 117 | 0.590 |
Why?
|
| Central Nervous System | 2 | 2016 | 151 | 0.570 |
Why?
|
| Antibodies | 5 | 2018 | 350 | 0.570 |
Why?
|
| Propylene Glycols | 5 | 2015 | 30 | 0.570 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2012 | 378 | 0.570 |
Why?
|
| Sphingosine | 5 | 2015 | 71 | 0.560 |
Why?
|
| Male | 64 | 2021 | 40956 | 0.550 |
Why?
|
| Gene Expression Regulation | 5 | 2019 | 1920 | 0.550 |
Why?
|
| Female | 69 | 2023 | 44507 | 0.540 |
Why?
|
| Hospitalization | 1 | 2021 | 848 | 0.530 |
Why?
|
| Patient Preference | 1 | 2016 | 105 | 0.520 |
Why?
|
| Limbic Encephalitis | 2 | 2018 | 11 | 0.510 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 763 | 0.510 |
Why?
|
| Herpesviridae | 1 | 2014 | 14 | 0.510 |
Why?
|
| Herpesviridae Infections | 1 | 2014 | 46 | 0.500 |
Why?
|
| Cognition | 4 | 2013 | 570 | 0.500 |
Why?
|
| Cytokines | 4 | 2007 | 776 | 0.490 |
Why?
|
| Monocytes | 8 | 2009 | 214 | 0.470 |
Why?
|
| Interferon-gamma | 8 | 2007 | 444 | 0.460 |
Why?
|
| Astrocytes | 4 | 2004 | 139 | 0.460 |
Why?
|
| Interferons | 2 | 2024 | 133 | 0.440 |
Why?
|
| Lymphocyte Activation | 16 | 2009 | 728 | 0.440 |
Why?
|
| Immunotherapy | 2 | 2014 | 629 | 0.430 |
Why?
|
| Crotonates | 2 | 2021 | 11 | 0.400 |
Why?
|
| Toluidines | 2 | 2021 | 17 | 0.400 |
Why?
|
| Hydroxybutyrates | 2 | 2021 | 27 | 0.400 |
Why?
|
| Natalizumab | 3 | 2021 | 21 | 0.390 |
Why?
|
| Optic Neuritis | 3 | 2009 | 10 | 0.380 |
Why?
|
| Glatiramer Acetate | 4 | 2021 | 14 | 0.380 |
Why?
|
| Nitriles | 2 | 2021 | 149 | 0.380 |
Why?
|
| Autoantibodies | 5 | 2018 | 267 | 0.380 |
Why?
|
| Time Factors | 10 | 2019 | 5209 | 0.370 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2021 | 206 | 0.360 |
Why?
|
| Adrenocorticotropic Hormone | 6 | 1992 | 131 | 0.350 |
Why?
|
| 4-Aminopyridine | 1 | 2009 | 32 | 0.350 |
Why?
|
| Potassium Channel Blockers | 1 | 2009 | 64 | 0.340 |
Why?
|
| Myelitis, Transverse | 1 | 2008 | 10 | 0.330 |
Why?
|
| Salivary Glands, Minor | 1 | 2008 | 9 | 0.330 |
Why?
|
| Submandibular Gland Diseases | 1 | 2008 | 9 | 0.330 |
Why?
|
| Lymphocytes | 8 | 2019 | 464 | 0.330 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2009 | 122 | 0.320 |
Why?
|
| Heptanoic Acids | 1 | 2008 | 72 | 0.320 |
Why?
|
| Signal Transduction | 5 | 2023 | 3241 | 0.310 |
Why?
|
| Spinal Cord | 4 | 2020 | 249 | 0.310 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 3 | 2004 | 57 | 0.310 |
Why?
|
| Neuropsychological Tests | 5 | 2013 | 502 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2015 | 1961 | 0.300 |
Why?
|
| B-Lymphocytes | 5 | 2007 | 724 | 0.300 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2007 | 27 | 0.300 |
Why?
|
| Pyrroles | 1 | 2008 | 184 | 0.300 |
Why?
|
| Cyclosporine | 2 | 2021 | 234 | 0.290 |
Why?
|
| Propensity Score | 2 | 2021 | 136 | 0.290 |
Why?
|
| Inflammation | 3 | 2008 | 920 | 0.290 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 7 | 1991 | 95 | 0.280 |
Why?
|
| Biomarkers | 5 | 2024 | 1718 | 0.280 |
Why?
|
| Neoplasms | 1 | 2021 | 2897 | 0.280 |
Why?
|
| Depression | 3 | 2013 | 473 | 0.270 |
Why?
|
| Azathioprine | 3 | 2023 | 125 | 0.260 |
Why?
|
| Myelin-Associated Glycoprotein | 1 | 2004 | 6 | 0.250 |
Why?
|
| Brain | 10 | 2023 | 2216 | 0.250 |
Why?
|
| Epilepsy | 3 | 2018 | 395 | 0.250 |
Why?
|
| Dependovirus | 1 | 2004 | 33 | 0.250 |
Why?
|
| Mycophenolic Acid | 2 | 2023 | 87 | 0.250 |
Why?
|
| Psychometrics | 3 | 2012 | 327 | 0.250 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2021 | 272 | 0.250 |
Why?
|
| Rituximab | 2 | 2023 | 116 | 0.250 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 1995 | 683 | 0.250 |
Why?
|
| Metallothionein | 1 | 2024 | 13 | 0.240 |
Why?
|
| Recombinant Proteins | 8 | 2005 | 1014 | 0.240 |
Why?
|
| Young Adult | 10 | 2023 | 5974 | 0.240 |
Why?
|
| Clostridium perfringens | 1 | 2023 | 7 | 0.230 |
Why?
|
| Apolipoproteins E | 1 | 2004 | 129 | 0.230 |
Why?
|
| Autoantigens | 1 | 2004 | 127 | 0.230 |
Why?
|
| Interleukin-1 | 5 | 1994 | 71 | 0.230 |
Why?
|
| Adolescent | 13 | 2023 | 8979 | 0.230 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2020 | 263 | 0.230 |
Why?
|
| Dexamethasone | 5 | 1994 | 326 | 0.230 |
Why?
|
| Blood-Brain Barrier | 1 | 2023 | 70 | 0.220 |
Why?
|
| Animals | 16 | 2023 | 26581 | 0.220 |
Why?
|
| Longitudinal Studies | 4 | 2013 | 1019 | 0.220 |
Why?
|
| Cladribine | 2 | 2021 | 35 | 0.220 |
Why?
|
| Immunity, Humoral | 1 | 2023 | 67 | 0.220 |
Why?
|
| Genetic Vectors | 1 | 2004 | 439 | 0.220 |
Why?
|
| Alemtuzumab | 2 | 2021 | 83 | 0.220 |
Why?
|
| Macular Edema | 2 | 2013 | 50 | 0.220 |
Why?
|
| RNA, Messenger | 4 | 2008 | 1981 | 0.210 |
Why?
|
| Prion Diseases | 1 | 2022 | 32 | 0.210 |
Why?
|
| Neurology | 2 | 2013 | 70 | 0.210 |
Why?
|
| Disease Progression | 4 | 2018 | 1531 | 0.210 |
Why?
|
| Antiviral Agents | 2 | 2023 | 510 | 0.210 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1993 | 158 | 0.210 |
Why?
|
| Risk Factors | 3 | 2021 | 5416 | 0.210 |
Why?
|
| Follow-Up Studies | 8 | 2018 | 3636 | 0.200 |
Why?
|
| Cyclophosphamide | 2 | 2021 | 299 | 0.200 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 293 | 0.200 |
Why?
|
| Treatment Outcome | 10 | 2021 | 7988 | 0.200 |
Why?
|
| Alzheimer Disease | 2 | 2004 | 470 | 0.200 |
Why?
|
| Phosphoproteins | 1 | 2002 | 254 | 0.200 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2012 | 376 | 0.200 |
Why?
|
| Mitoxantrone | 1 | 2021 | 68 | 0.200 |
Why?
|
| Brain Stem | 2 | 2020 | 165 | 0.190 |
Why?
|
| Vaccination | 1 | 2022 | 254 | 0.190 |
Why?
|
| Interleukin-6 | 4 | 1995 | 256 | 0.190 |
Why?
|
| Neurologic Examination | 2 | 2013 | 118 | 0.190 |
Why?
|
| Retinal Ganglion Cells | 2 | 2012 | 66 | 0.190 |
Why?
|
| Methotrexate | 1 | 2021 | 249 | 0.190 |
Why?
|
| Disability Evaluation | 5 | 2015 | 136 | 0.190 |
Why?
|
| Memory | 2 | 2013 | 225 | 0.190 |
Why?
|
| Alprostadil | 3 | 1994 | 25 | 0.180 |
Why?
|
| Endothelial Cells | 1 | 2023 | 428 | 0.180 |
Why?
|
| Cognition Disorders | 2 | 2012 | 236 | 0.180 |
Why?
|
| Electrophoresis | 1 | 1999 | 55 | 0.180 |
Why?
|
| DNA Probes | 1 | 1999 | 77 | 0.180 |
Why?
|
| Double-Blind Method | 7 | 2015 | 1823 | 0.180 |
Why?
|
| Trans-Activators | 1 | 2002 | 429 | 0.180 |
Why?
|
| Arousal | 1 | 2020 | 170 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 930 | 0.180 |
Why?
|
| Open Reading Frames | 1 | 2019 | 117 | 0.180 |
Why?
|
| T-Lymphocytes, Cytotoxic | 5 | 1988 | 315 | 0.180 |
Why?
|
| Antigens, Surface | 6 | 1987 | 101 | 0.170 |
Why?
|
| Repressor Proteins | 1 | 2002 | 403 | 0.170 |
Why?
|
| Receptors, Adrenergic, beta | 5 | 1993 | 72 | 0.170 |
Why?
|
| Survival Analysis | 4 | 2012 | 1538 | 0.170 |
Why?
|
| Comorbidity | 2 | 2021 | 943 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 9 | 2008 | 1376 | 0.170 |
Why?
|
| DNA-Binding Proteins | 2 | 2002 | 1208 | 0.170 |
Why?
|
| Gray Matter | 1 | 2018 | 33 | 0.170 |
Why?
|
| Polyethylene Glycols | 1 | 2021 | 363 | 0.170 |
Why?
|
| Interferon Regulatory Factor-1 | 2 | 2012 | 19 | 0.170 |
Why?
|
| Incidence | 2 | 2021 | 1576 | 0.170 |
Why?
|
| Reproducibility of Results | 8 | 2018 | 2705 | 0.160 |
Why?
|
| RNA, Long Noncoding | 1 | 2019 | 102 | 0.160 |
Why?
|
| STAT1 Transcription Factor | 2 | 2012 | 52 | 0.160 |
Why?
|
| Misoprostol | 2 | 1995 | 15 | 0.160 |
Why?
|
| Hydrocortisone | 6 | 1992 | 298 | 0.160 |
Why?
|
| Tomography, Optical Coherence | 4 | 2013 | 130 | 0.160 |
Why?
|
| Glutamate Decarboxylase | 1 | 2018 | 32 | 0.160 |
Why?
|
| Autoimmune Diseases | 2 | 1998 | 241 | 0.160 |
Why?
|
| Encephalitis | 1 | 2018 | 104 | 0.150 |
Why?
|
| Myxovirus Resistance Proteins | 2 | 2010 | 7 | 0.150 |
Why?
|
| United States | 3 | 2021 | 6665 | 0.150 |
Why?
|
| Sympathetic Nervous System | 5 | 1993 | 104 | 0.150 |
Why?
|
| Cells, Cultured | 9 | 2002 | 2818 | 0.150 |
Why?
|
| Mice | 7 | 2023 | 11352 | 0.150 |
Why?
|
| Databases, Factual | 1 | 2021 | 812 | 0.150 |
Why?
|
| Myelin Sheath | 2 | 2016 | 84 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 559 | 0.150 |
Why?
|
| Logistic Models | 1 | 2021 | 1185 | 0.150 |
Why?
|
| Transcriptome | 2 | 2019 | 580 | 0.150 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 6501 | 0.150 |
Why?
|
| Quality of Life | 3 | 2013 | 1583 | 0.150 |
Why?
|
| Immunosenescence | 1 | 2016 | 4 | 0.150 |
Why?
|
| Cryptococcosis | 1 | 2016 | 11 | 0.150 |
Why?
|
| Aged | 11 | 2023 | 18402 | 0.140 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 2501 | 0.140 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2018 | 122 | 0.140 |
Why?
|
| Transcription Factors | 2 | 2012 | 1565 | 0.140 |
Why?
|
| Internet | 2 | 2016 | 312 | 0.140 |
Why?
|
| Estriol | 1 | 2015 | 8 | 0.140 |
Why?
|
| Self Administration | 1 | 2016 | 73 | 0.140 |
Why?
|
| Prolactin | 2 | 1993 | 88 | 0.140 |
Why?
|
| Flow Cytometry | 5 | 2009 | 679 | 0.140 |
Why?
|
| Receptors, Immunologic | 3 | 2009 | 135 | 0.140 |
Why?
|
| Trigeminal Neuralgia | 1 | 1995 | 6 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2009 | 425 | 0.130 |
Why?
|
| Medication Reconciliation | 1 | 2015 | 6 | 0.130 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2014 | 4 | 0.130 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 1801 | 0.130 |
Why?
|
| Mifepristone | 1 | 1994 | 33 | 0.130 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 1995 | 50 | 0.130 |
Why?
|
| Prostaglandins | 1 | 1994 | 43 | 0.130 |
Why?
|
| Herpesvirus 3, Human | 1 | 2015 | 43 | 0.130 |
Why?
|
| Choice Behavior | 1 | 2016 | 160 | 0.130 |
Why?
|
| Arachidonic Acid | 1 | 1994 | 63 | 0.130 |
Why?
|
| Disabled Persons | 2 | 2012 | 67 | 0.130 |
Why?
|
| Medication Adherence | 1 | 2016 | 129 | 0.120 |
Why?
|
| Herpes Zoster | 1 | 2015 | 78 | 0.120 |
Why?
|
| Obesity | 1 | 2021 | 963 | 0.120 |
Why?
|
| Nervous System Diseases | 2 | 2012 | 151 | 0.120 |
Why?
|
| DNA | 4 | 2013 | 1294 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2013 | 2356 | 0.120 |
Why?
|
| Adrenal Glands | 1 | 1994 | 76 | 0.120 |
Why?
|
| Behavioral Symptoms | 1 | 2013 | 15 | 0.120 |
Why?
|
| CD8 Antigens | 5 | 1993 | 82 | 0.120 |
Why?
|
| Protein Isoforms | 1 | 2014 | 270 | 0.120 |
Why?
|
| Trail Making Test | 1 | 2013 | 3 | 0.120 |
Why?
|
| Stroop Test | 1 | 2013 | 9 | 0.120 |
Why?
|
| Temporal Lobe | 2 | 2018 | 172 | 0.120 |
Why?
|
| Intelligence Tests | 1 | 2013 | 38 | 0.120 |
Why?
|
| Dizocilpine Maleate | 1 | 1992 | 12 | 0.110 |
Why?
|
| Interferon Regulatory Factors | 1 | 2013 | 67 | 0.110 |
Why?
|
| Fatigue | 1 | 2013 | 174 | 0.110 |
Why?
|
| N-Methylaspartate | 1 | 1992 | 51 | 0.110 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 187 | 0.110 |
Why?
|
| Jurkat Cells | 1 | 2012 | 77 | 0.110 |
Why?
|
| Vitreous Body | 1 | 1992 | 54 | 0.110 |
Why?
|
| Hemianopsia | 1 | 2012 | 4 | 0.110 |
Why?
|
| Glutamates | 1 | 1992 | 89 | 0.110 |
Why?
|
| Antigens, CD | 2 | 1991 | 458 | 0.110 |
Why?
|
| Tetanus | 1 | 1992 | 1 | 0.110 |
Why?
|
| Optic Nerve | 1 | 2012 | 35 | 0.110 |
Why?
|
| Cost of Illness | 1 | 2013 | 150 | 0.110 |
Why?
|
| Glucocorticoids | 1 | 1994 | 352 | 0.110 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 2004 | 132 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2010 | 689 | 0.100 |
Why?
|
| Immunization | 1 | 1992 | 158 | 0.100 |
Why?
|
| Diabetic Retinopathy | 1 | 1992 | 87 | 0.100 |
Why?
|
| Antibodies, Bacterial | 1 | 1992 | 95 | 0.100 |
Why?
|
| Diagnosis, Differential | 4 | 2012 | 1565 | 0.100 |
Why?
|
| Disease Susceptibility | 2 | 2011 | 193 | 0.100 |
Why?
|
| Visual Pathways | 1 | 2012 | 152 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2023 | 8475 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2013 | 2767 | 0.100 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2010 | 36 | 0.100 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 894 | 0.100 |
Why?
|
| Retina | 1 | 1992 | 213 | 0.100 |
Why?
|
| Drug Administration Schedule | 4 | 2017 | 916 | 0.090 |
Why?
|
| Electroencephalography | 3 | 2009 | 707 | 0.090 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1991 | 203 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2015 | 2261 | 0.090 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 2 | 2002 | 9 | 0.090 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2009 | 16 | 0.090 |
Why?
|
| Psychomotor Performance | 1 | 2013 | 492 | 0.090 |
Why?
|
| Health Status | 1 | 2012 | 360 | 0.090 |
Why?
|
| Up-Regulation | 4 | 2011 | 712 | 0.090 |
Why?
|
| Antibodies, Neutralizing | 1 | 2010 | 112 | 0.090 |
Why?
|
| Injections, Intramuscular | 2 | 2021 | 62 | 0.090 |
Why?
|
| Sympathectomy, Chemical | 1 | 1989 | 6 | 0.090 |
Why?
|
| Hydroxydopamines | 1 | 1989 | 7 | 0.090 |
Why?
|
| Nerve Fibers | 1 | 2009 | 46 | 0.090 |
Why?
|
| Recurrence | 4 | 2023 | 1139 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2004 | 557 | 0.090 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 1990 | 0.090 |
Why?
|
| Organ Size | 3 | 2018 | 364 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 5 | 2009 | 316 | 0.090 |
Why?
|
| Neurosecretory Systems | 1 | 1989 | 35 | 0.090 |
Why?
|
| Tachycardia | 1 | 2009 | 35 | 0.090 |
Why?
|
| Gyrus Cinguli | 1 | 2009 | 45 | 0.090 |
Why?
|
| Memory Disorders | 1 | 2009 | 69 | 0.080 |
Why?
|
| Neutralization Tests | 1 | 2008 | 77 | 0.080 |
Why?
|
| Sjogren's Syndrome | 1 | 2008 | 30 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2009 | 286 | 0.080 |
Why?
|
| Drug Overdose | 1 | 2009 | 65 | 0.080 |
Why?
|
| Spleen | 1 | 1989 | 430 | 0.080 |
Why?
|
| In Vitro Techniques | 3 | 1995 | 989 | 0.080 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 160 | 0.080 |
Why?
|
| Principal Component Analysis | 1 | 2008 | 155 | 0.080 |
Why?
|
| Genes, Reporter | 1 | 2008 | 268 | 0.080 |
Why?
|
| Killer Cells, Natural | 1 | 1989 | 267 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2008 | 912 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 364 | 0.080 |
Why?
|
| Rats | 5 | 1994 | 3990 | 0.080 |
Why?
|
| Interferon-alpha | 2 | 2002 | 233 | 0.080 |
Why?
|
| Hypoxia | 1 | 1992 | 641 | 0.080 |
Why?
|
| Lymphocyte Subsets | 1 | 2007 | 64 | 0.070 |
Why?
|
| Cytotoxicity, Immunologic | 5 | 1993 | 213 | 0.070 |
Why?
|
| Administration, Oral | 3 | 2014 | 684 | 0.070 |
Why?
|
| Kinetics | 2 | 2004 | 1513 | 0.070 |
Why?
|
| Lymphokines | 1 | 1986 | 76 | 0.070 |
Why?
|
| Growth Substances | 1 | 1986 | 80 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2012 | 504 | 0.070 |
Why?
|
| Cholesterol | 1 | 2008 | 356 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 879 | 0.070 |
Why?
|
| Heart | 1 | 2009 | 539 | 0.070 |
Why?
|
| Immunoglobulin G | 8 | 1986 | 456 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2011 | 2270 | 0.070 |
Why?
|
| Rats, Inbred Lew | 3 | 1994 | 186 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 339 | 0.070 |
Why?
|
| Myelin Basic Protein | 2 | 1995 | 49 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2010 | 628 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2010 | 1621 | 0.060 |
Why?
|
| Indomethacin | 2 | 1994 | 59 | 0.060 |
Why?
|
| Myelin Proteins | 1 | 2004 | 13 | 0.060 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2004 | 9 | 0.060 |
Why?
|
| Concanavalin A | 6 | 1998 | 52 | 0.060 |
Why?
|
| Aging | 1 | 1989 | 691 | 0.060 |
Why?
|
| Biopsy | 1 | 2008 | 1161 | 0.060 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2004 | 58 | 0.060 |
Why?
|
| Antibody Specificity | 1 | 2004 | 129 | 0.060 |
Why?
|
| Brain Diseases | 2 | 1983 | 180 | 0.060 |
Why?
|
| Lymphocyte Count | 1 | 2004 | 94 | 0.060 |
Why?
|
| Atrophy | 2 | 2018 | 117 | 0.060 |
Why?
|
| Prevalence | 1 | 2008 | 1239 | 0.060 |
Why?
|
| B7-1 Antigen | 2 | 2009 | 75 | 0.060 |
Why?
|
| Glycosylation | 1 | 2004 | 129 | 0.060 |
Why?
|
| Neurons | 1 | 1992 | 1546 | 0.060 |
Why?
|
| Echocardiography | 1 | 2009 | 911 | 0.060 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2018 | 66 | 0.060 |
Why?
|
| Aquaporin 4 | 1 | 2023 | 8 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2003 | 274 | 0.060 |
Why?
|
| Interferon Regulatory Factor-2 | 1 | 2002 | 4 | 0.060 |
Why?
|
| Demography | 1 | 2023 | 177 | 0.060 |
Why?
|
| Fluorescein Angiography | 2 | 2013 | 96 | 0.050 |
Why?
|
| Munchausen Syndrome | 1 | 1982 | 2 | 0.050 |
Why?
|
| Tyrosine | 1 | 2002 | 133 | 0.050 |
Why?
|
| Cell Line | 4 | 2014 | 2468 | 0.050 |
Why?
|
| Serine | 1 | 2002 | 99 | 0.050 |
Why?
|
| Visual Acuity | 2 | 2013 | 194 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2004 | 371 | 0.050 |
Why?
|
| Depressive Disorder | 3 | 1988 | 218 | 0.050 |
Why?
|
| Alleles | 1 | 2004 | 1127 | 0.050 |
Why?
|
| Hippocampus | 1 | 2004 | 442 | 0.050 |
Why?
|
| Vitamin D | 1 | 2023 | 261 | 0.050 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1992 | 137 | 0.050 |
Why?
|
| Affect | 1 | 2003 | 386 | 0.050 |
Why?
|
| Hypertension | 1 | 2009 | 1141 | 0.050 |
Why?
|
| Pokeweed Mitogens | 5 | 1986 | 10 | 0.050 |
Why?
|
| Macrophages | 2 | 1998 | 554 | 0.050 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1999 | 19 | 0.050 |
Why?
|
| Acrylic Resins | 1 | 1999 | 22 | 0.050 |
Why?
|
| CD2 Antigens | 2 | 1991 | 22 | 0.050 |
Why?
|
| Epitopes | 2 | 1993 | 255 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2002 | 1106 | 0.040 |
Why?
|
| Gene Expression | 1 | 2004 | 1284 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 1982 | 324 | 0.040 |
Why?
|
| Macromolecular Substances | 1 | 1999 | 177 | 0.040 |
Why?
|
| Secondary Prevention | 2 | 2014 | 162 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2002 | 263 | 0.040 |
Why?
|
| Corpus Callosum | 1 | 2018 | 56 | 0.040 |
Why?
|
| Neuritis | 1 | 1998 | 8 | 0.040 |
Why?
|
| Rosette Formation | 2 | 1991 | 34 | 0.040 |
Why?
|
| Cell Separation | 3 | 2009 | 196 | 0.040 |
Why?
|
| Carboxy-Lyases | 1 | 2018 | 22 | 0.040 |
Why?
|
| Artifacts | 1 | 1999 | 244 | 0.040 |
Why?
|
| White Matter | 1 | 2018 | 80 | 0.040 |
Why?
|
| Receptors, Glucocorticoid | 3 | 1988 | 120 | 0.040 |
Why?
|
| Apoptosis | 1 | 2004 | 1683 | 0.040 |
Why?
|
| Thalamus | 1 | 2018 | 132 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2004 | 3092 | 0.040 |
Why?
|
| Drug Interactions | 1 | 1998 | 248 | 0.040 |
Why?
|
| Gadolinium | 1 | 2017 | 103 | 0.040 |
Why?
|
| Proteins | 1 | 2002 | 777 | 0.040 |
Why?
|
| Mast Cells | 1 | 1996 | 92 | 0.040 |
Why?
|
| Personality | 1 | 2018 | 133 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 1996 | 303 | 0.040 |
Why?
|
| Species Specificity | 1 | 1998 | 678 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2017 | 113 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 1673 | 0.030 |
Why?
|
| Lipopolysaccharides | 2 | 1994 | 286 | 0.030 |
Why?
|
| Protein Binding | 1 | 1999 | 1456 | 0.030 |
Why?
|
| Prostaglandins E, Synthetic | 1 | 1995 | 3 | 0.030 |
Why?
|
| Mice, Inbred DBA | 2 | 1993 | 148 | 0.030 |
Why?
|
| Peptides | 2 | 2009 | 639 | 0.030 |
Why?
|
| Seizures | 1 | 2018 | 295 | 0.030 |
Why?
|
| Prions | 1 | 1995 | 54 | 0.030 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2015 | 37 | 0.030 |
Why?
|
| Child | 4 | 2011 | 6926 | 0.030 |
Why?
|
| Secretory Rate | 1 | 1994 | 13 | 0.030 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1994 | 25 | 0.030 |
Why?
|
| STAT Transcription Factors | 1 | 2014 | 18 | 0.030 |
Why?
|
| Cyclic AMP | 2 | 1993 | 273 | 0.030 |
Why?
|
| Janus Kinases | 1 | 2014 | 23 | 0.030 |
Why?
|
| Corticotropin-Releasing Hormone | 2 | 1992 | 44 | 0.030 |
Why?
|
| Hormones | 1 | 1995 | 140 | 0.030 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2014 | 45 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1995 | 293 | 0.030 |
Why?
|
| Edema | 1 | 1994 | 71 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2014 | 25 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 244 | 0.030 |
Why?
|
| Drug Combinations | 1 | 1994 | 224 | 0.030 |
Why?
|
| Antibody-Producing Cells | 2 | 1984 | 16 | 0.030 |
Why?
|
| Canada | 1 | 2014 | 204 | 0.030 |
Why?
|
| Cerebrospinal Fluid | 2 | 1984 | 32 | 0.030 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1993 | 10 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 218 | 0.030 |
Why?
|
| Interleukin-2 | 3 | 1993 | 249 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 373 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1993 | 71 | 0.030 |
Why?
|
| Ophthalmoscopy | 1 | 2013 | 12 | 0.030 |
Why?
|
| Clone Cells | 1 | 1993 | 213 | 0.030 |
Why?
|
| Consensus | 1 | 2015 | 335 | 0.030 |
Why?
|
| Kynurenic Acid | 1 | 1992 | 7 | 0.030 |
Why?
|
| Uveitis | 1 | 2013 | 29 | 0.030 |
Why?
|
| Aqueous Humor | 1 | 1992 | 23 | 0.030 |
Why?
|
| Dextromethorphan | 1 | 1992 | 11 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1992 | 91 | 0.030 |
Why?
|
| Arginine Vasopressin | 1 | 1992 | 47 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 1993 | 163 | 0.030 |
Why?
|
| Rats, Inbred Strains | 1 | 1992 | 312 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 736 | 0.030 |
Why?
|
| Visual Field Tests | 1 | 2012 | 14 | 0.030 |
Why?
|
| NADH Dehydrogenase | 1 | 2012 | 22 | 0.030 |
Why?
|
| Vitrectomy | 1 | 1992 | 52 | 0.030 |
Why?
|
| Clostridium tetani | 1 | 1992 | 2 | 0.030 |
Why?
|
| I-kappa B Kinase | 1 | 2012 | 37 | 0.030 |
Why?
|
| Body Weight | 1 | 1994 | 459 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 22 | 0.030 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 1994 | 182 | 0.030 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2012 | 41 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 1992 | 152 | 0.030 |
Why?
|
| Interleukins | 1 | 1992 | 134 | 0.030 |
Why?
|
| Receptors, Muscarinic | 1 | 1992 | 49 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 1993 | 425 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2011 | 87 | 0.030 |
Why?
|
| Outpatients | 1 | 2012 | 94 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2012 | 130 | 0.030 |
Why?
|
| Stimulation, Chemical | 1 | 1991 | 63 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2011 | 970 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2014 | 447 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2012 | 153 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 1998 | 2232 | 0.030 |
Why?
|
| Age of Onset | 1 | 2012 | 310 | 0.020 |
Why?
|
| Dystonia | 1 | 1991 | 29 | 0.020 |
Why?
|
| Sheep | 1 | 1991 | 239 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1993 | 372 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 1995 | 584 | 0.020 |
Why?
|
| Antioxidants | 1 | 2012 | 223 | 0.020 |
Why?
|
| Evoked Potentials, Visual | 1 | 1991 | 87 | 0.020 |
Why?
|
| Cause of Death | 1 | 2012 | 277 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 2062 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 1994 | 375 | 0.020 |
Why?
|
| Self Report | 1 | 2012 | 288 | 0.020 |
Why?
|
| Lysophospholipids | 1 | 2010 | 63 | 0.020 |
Why?
|
| Leukocyte Count | 3 | 1986 | 220 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2010 | 60 | 0.020 |
Why?
|
| Prognosis | 1 | 2018 | 3674 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 172 | 0.020 |
Why?
|
| Pattern Recognition, Visual | 1 | 1991 | 151 | 0.020 |
Why?
|
| B7-2 Antigen | 1 | 2009 | 40 | 0.020 |
Why?
|
| Plasma | 1 | 2010 | 50 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 176 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2009 | 16 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 3030 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 678 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 677 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 860 | 0.020 |
Why?
|
| Oxidopamine | 1 | 1989 | 8 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 309 | 0.020 |
Why?
|
| Mice, Inbred CBA | 1 | 1989 | 52 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2009 | 28 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2013 | 375 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 857 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 174 | 0.020 |
Why?
|
| Immunity, Cellular | 2 | 1986 | 177 | 0.020 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1989 | 50 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1804 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2010 | 476 | 0.020 |
Why?
|
| Mitochondria | 1 | 2012 | 535 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 526 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 84 | 0.020 |
Why?
|
| Reflex | 1 | 1988 | 79 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2009 | 428 | 0.020 |
Why?
|
| H-2 Antigens | 1 | 1987 | 58 | 0.020 |
Why?
|
| Myasthenia Gravis | 1 | 2008 | 83 | 0.020 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1987 | 49 | 0.020 |
Why?
|
| Antibody Formation | 1 | 1988 | 171 | 0.020 |
Why?
|
| Monitoring, Immunologic | 1 | 2007 | 17 | 0.020 |
Why?
|
| Virus Diseases | 1 | 1988 | 97 | 0.020 |
Why?
|
| Attention | 1 | 2011 | 388 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2007 | 55 | 0.020 |
Why?
|
| Deltaretrovirus | 1 | 1986 | 2 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1987 | 245 | 0.020 |
Why?
|
| Glucose-6-Phosphate Isomerase | 1 | 1986 | 8 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 1850 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1986 | 173 | 0.020 |
Why?
|
| Suppressor Factors, Immunologic | 1 | 1986 | 2 | 0.020 |
Why?
|
| Cyclosporins | 1 | 1986 | 59 | 0.020 |
Why?
|
| Skin | 1 | 1990 | 554 | 0.020 |
Why?
|
| Lectins | 1 | 1986 | 84 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 937 | 0.020 |
Why?
|
| Genes | 1 | 1987 | 305 | 0.020 |
Why?
|
| Pregnancy | 1 | 1993 | 2893 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1988 | 782 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2006 | 93 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 1986 | 148 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 479 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2010 | 535 | 0.020 |
Why?
|
| Safety | 1 | 2006 | 152 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1986 | 435 | 0.020 |
Why?
|
| Lymphoma | 1 | 1986 | 262 | 0.020 |
Why?
|
| Neopterin | 1 | 2004 | 2 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2006 | 268 | 0.020 |
Why?
|
| Leukemia | 1 | 1986 | 320 | 0.020 |
Why?
|
| CD3 Complex | 1 | 1984 | 135 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 1620 | 0.010 |
Why?
|
| Mutation | 1 | 1995 | 3967 | 0.010 |
Why?
|
| Encephalomyelitis | 1 | 1983 | 6 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2009 | 1578 | 0.010 |
Why?
|
| Dementia | 1 | 1985 | 187 | 0.010 |
Why?
|
| Hemolytic Plaque Technique | 1 | 1983 | 12 | 0.010 |
Why?
|
| Spinal Cord Diseases | 1 | 1983 | 29 | 0.010 |
Why?
|
| Algorithms | 1 | 2011 | 1830 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1983 | 74 | 0.010 |
Why?
|
| Antigens | 1 | 1984 | 228 | 0.010 |
Why?
|
| Granuloma | 1 | 1983 | 65 | 0.010 |
Why?
|
| Amputation, Traumatic | 1 | 1982 | 9 | 0.010 |
Why?
|
| Finger Injuries | 1 | 1982 | 11 | 0.010 |
Why?
|
| Phytohemagglutinins | 3 | 1988 | 22 | 0.010 |
Why?
|
| Age Factors | 2 | 1985 | 1849 | 0.010 |
Why?
|
| Sensation | 1 | 1982 | 45 | 0.010 |
Why?
|
| Isoantigens | 3 | 1986 | 66 | 0.010 |
Why?
|
| Pindolol | 2 | 1991 | 6 | 0.010 |
Why?
|
| Neural Pathways | 1 | 1982 | 308 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 1988 | 806 | 0.010 |
Why?
|
| Chymases | 1 | 1996 | 11 | 0.010 |
Why?
|
| Tryptases | 1 | 1996 | 12 | 0.010 |
Why?
|
| Cell Count | 1 | 1997 | 195 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1983 | 1458 | 0.010 |
Why?
|
| Immunoglobulin E | 1 | 1996 | 144 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 1996 | 145 | 0.010 |
Why?
|
| Evoked Potentials | 1 | 1996 | 190 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 1984 | 42 | 0.010 |
Why?
|
| Creatinine | 1 | 1995 | 338 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1996 | 666 | 0.010 |
Why?
|
| Thromboplastin | 1 | 1993 | 7 | 0.010 |
Why?
|
| Epinephrine | 1 | 1993 | 84 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1996 | 530 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1993 | 167 | 0.010 |
Why?
|
| N-Methylscopolamine | 1 | 1992 | 2 | 0.010 |
Why?
|
| Scopolamine Derivatives | 1 | 1992 | 4 | 0.010 |
Why?
|
| Methods | 1 | 1991 | 152 | 0.010 |
Why?
|
| CD28 Antigens | 1 | 1991 | 88 | 0.010 |
Why?
|
| Neurons, Afferent | 1 | 1991 | 79 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1990 | 145 | 0.010 |
Why?
|
| Reaction Time | 1 | 1991 | 309 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 1990 | 347 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 1990 | 435 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1986 | 44 | 0.000 |
Why?
|
| Circadian Rhythm | 1 | 1988 | 303 | 0.000 |
Why?
|
| Herpesvirus 4, Human | 1 | 1986 | 114 | 0.000 |
Why?
|
| Cytoplasm | 1 | 1985 | 281 | 0.000 |
Why?
|
| Mice, Inbred BALB C | 1 | 1987 | 1047 | 0.000 |
Why?
|
| Mitomycins | 1 | 1984 | 13 | 0.000 |
Why?
|
| Lymphocyte Cooperation | 1 | 1984 | 4 | 0.000 |
Why?
|
| Mitomycin | 1 | 1984 | 29 | 0.000 |
Why?
|
| Models, Biological | 1 | 1991 | 1749 | 0.000 |
Why?
|
| Sex Factors | 1 | 1985 | 1054 | 0.000 |
Why?
|
| Phenotype | 1 | 1986 | 2377 | 0.000 |
Why?
|